supernus pharmaceuticals inc (SUPN) Snapshot

Supernus Pharmaceuticals, Inc. received a tentative approval letter from the Food & Drug Administration for Trokendi XR(TM), a novel once-daily extended release formulation of topiramate (formerly known as SPN-538). The letter states that the FDA completed its review of the Trokendi XR(TM) New Drug Application as amended in December 2012 and the product is tentatively approved for use as recommended in the submitted and agreed-upon labeling.

Supernus Pharmaceuticals, Inc. Presents at Jefferies 2013 Global Healthcare Conference, Jun-04-2013 10:00 AM. Venue: Grand Hyatt Hotel, 109 East 42nd Street at Grand Central, New York, New York, United States. Speakers: Jack A. Khattar, Founder, Chief Executive Officer, President and Director.

Supernus Pharmaceuticals, Inc. announced unaudited consolidated financial results for the first quarter ended March 31, 2013. For the quarter, the company reported revenues of $147,000 against $208,000 a year ago. Operating loss was $17,908,000 against $7,878,000 a year ago. Net loss was $18,414,000 against $9,277,000 a year ago. Net loss attributable to common shareholders was $18,414,000 or $0.60 per basic and diluted sharer against $10,135,000 or $6.05 per basic and diluted sharer a year ago. For the year 2013, In order to support both product launches and the continued development of the company's pipeline, the company projected cash burn for 2013 to range from $85 million to $95 million. The decrease of $10 million in projected cash burn from prior projection of $95 million to $105 million is primarily due to the refinancing of secured credit facility.